Related Experiment Videos
Ibuprofen: alternative treatment for patent ductus arteriosus
1The Women's Hospital of Texas, Houston, USA. melissa.flores@hcahealthcare.com
Insights
Ibuprofen shows promise as a safer alternative to indomethacin for closing patent ductus arteriosus in premature infants. Further U.S. clinical trials are needed to confirm its efficacy and safety.
Area of Science:
- Neonatal medicine
- Pediatric cardiology
- Pharmacology
Background:
- Patent ductus arteriosus (PDA) is a frequent complication in preterm neonates.
- Indomethacin, a common PDA treatment, has variable efficacy and significant side effects.
- Potential adverse effects of indomethacin include intraventricular hemorrhage and compromised organ blood flow.
Purpose of the Study:
- To evaluate ibuprofen as a potential alternative therapy for PDA closure in premature infants.
- To assess the safety and efficacy of ibuprofen compared to traditional treatments.
Main Methods:
- International research examining ibuprofen's use in PDA.
- Analysis of existing data on ibuprofen's effectiveness and side effect profile.
Main Results:
- Promising findings regarding ibuprofen's efficacy in PDA closure.
- Ibuprofen appears to be a viable alternative with a potentially improved safety profile.
Conclusions:
- Ibuprofen demonstrates potential as an effective and safer treatment for PDA in preterm neonates.
- The promising results warrant further investigation through U.S.-based clinical trials.
Abstract:
Patent ductus arteriosus (PDA) is a common problem for premature babies. Indomethacin, traditionally the treatment of choice for PDA closure, varies in effectiveness and can have serious side effects, such as intraventricular cerebral hemorrhage and decreased mesenteric and renal blood flow. Researchers abroad are examining the efficacy and safety of ibuprofen as an alternative PDA therapy. Their findings have been promising and indicate the need for clinical trials in the U.S.